Health Related Quality of Life in Patients with Neuroendocrine Tumors Compared with the General Norwegian Population

Overview

Journal Qual Life Res

Specialties Pharmacology
Rehabilitation Medicine

Date 2009 May 30

PMID 19479341

Citations 30

Authors

Trude Haugland

Morten H Vatn

Marijke Veenstra

Astrid Klopstad Wahl

Gerd Karin Natvig

Affiliations

Soon will be listed here.

Abstract

Purpose: Health related quality of life (HRQoL) was characterized among patients with neuroendocrine tumor (NET) and compared with the general Norwegian population.

Methods: A cross sectional, comparative design was chosen, and the samples comprised 196 NET patients and 5,258 individuals from the general Norwegian population. We used Chi-square cross tab calculations to evaluate sociodemographic characteristics, T-tests for independent samples and Analysis of Variance (ANOVA) in order to compare HRQoL (SF-36) scores across a range of background variables. Furthermore, T-tests were used to analyze differences in HRQoL scores between the samples.

Results: NET patients demonstrated significantly lower on all HRQoL subscales when compared with the general population with the lowest values on general health, physical limitation and vitality. Individuals above 70 years reported lower scores on physical functioning and physical limitations compared with those who were younger. Individuals with higher levels of education reported increased physical functioning compared with those with less education and full-time or part-time workers described higher physical functioning and less physical limitations compared with those who were retired.

Conclusions: All SF-36 HRQoL scores were significantly lower among the NET patients when compared with the general population. Assistance from health personnel to NET patients should focus on those domains.

Citing Articles

Lost in translation: evaluating the readability of online patient information for neuroendocrine tumors.

Paschke A, Grewal U Endocrine. 2023; 84(1):97-99.

PMID: 38010471 DOI: 10.1007/s12020-023-03607-0.

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.

Raj N, Cruz E, OShaughnessy S, Calderon C, Chou J, Capanu M JCO Oncol Pract. 2022; 18(9):e1533-e1541.

PMID: 35724357 PMC: 9509059. DOI: 10.1200/OP.22.00055.

Gosain R, Gupta M, Roy A, Strosberg J, Glaser K, Iyer R Cancers (Basel). 2022; 14(6).

PMID: 35326587 PMC: 8946839. DOI: 10.3390/cancers14061428.

Ronde E, Heidsma C, Eskes A, Schopman J, Nieveen van Dijkum E Eur J Cancer Care (Engl). 2021; 30(6):e13504.

PMID: 34462979 PMC: 9286581. DOI: 10.1111/ecc.13504.

Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.

Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Gomez M, Del Olmo-Garcia M, Lorenzo I Clin Transl Oncol. 2021; 23(10):2046-2056.

PMID: 34109562 PMC: 8390421. DOI: 10.1007/s12094-021-02608-7.

References

Hammerlid E, Taft C . Health-related quality of life in long-term head and neck cancer survivors: a comparison with general population norms. Br J Cancer. 2001; 84(2):149-56. PMC: 2363699. DOI: 10.1054/bjoc.2000.1576. View

McHorney C, Ware Jr J, Lu J, Sherbourne C . The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994; 32(1):40-66. DOI: 10.1097/00005650-199401000-00004. View

Boini S, Briancon S, Guillemin F, Galan P, Hercberg S . Impact of cancer occurrence on health-related quality of life: a longitudinal pre-post assessment. Health Qual Life Outcomes. 2004; 2:4. PMC: 317475. DOI: 10.1186/1477-7525-2-4. View

Larsson G, Widmark Peterson V, Lampic C, von Essen L, Sjoden P . Cancer patient and staff ratings of the importance of caring behaviors and their relations to patient anxiety and depression. J Adv Nurs. 1998; 27(4):855-64. DOI: 10.1046/j.1365-2648.1998.00583.x. View

Oberg K, Eriksson B . Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol. 1989; 28(3):425-31. DOI: 10.3109/02841868909111217. View

Frojd C, Larsson G, Lampic C, von Essen L . Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007; 5:18. PMC: 1852299. DOI: 10.1186/1477-7525-5-18. View

Hjermstad M, Fayers P, Bjordal K, Kaasa S . Using reference data on quality of life--the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer. 1998; 34(9):1381-9. DOI: 10.1016/s0959-8049(98)00136-1. View

Larsson G, Sjoden P, Oberg K, von Essen L . Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours. Ann Oncol. 2000; 10(11):1321-7. DOI: 10.1023/a:1008360718646. View

Berglund G, Liden A, Hansson M, Oberg K, Sjoden P, Nordin K . Quality of life in patients with multiple endocrine neoplasia type 1 (MEN 1). Fam Cancer. 2003; 2(1):27-33. DOI: 10.1023/a:1023252107120. View

10.

Saegrov S, Halding A . What is it like living with the diagnosis of cancer?. Eur J Cancer Care (Engl). 2004; 13(2):145-53. DOI: 10.1111/j.1365-2354.2004.00442.x. View

11.

Oberg K . Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther. 2003; 3(6):863-77. DOI: 10.1586/14737140.3.6.863. View

12.

Larsson G, von Essen L, Sjoden P . Quality of life in patients with endocrine tumors of the gastrointestinal tract: patient and staff perceptions. Cancer Nurs. 1998; 21(6):411-20. DOI: 10.1097/00002820-199812000-00005. View

13.

Larsson G, Sjoden P, Oberg K, Eriksson B, von Essen L . Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncol. 2002; 40(7):825-31. DOI: 10.1080/02841860152703445. View

14.

Oberg K, Astrup L, Eriksson B, Falkmer S, Falkmer U, Gustafsen J . Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol. 2004; 43(7):626-36. DOI: 10.1080/02841860410018584. View

15.

FRANK L, Kleinman L, Leidy N, LeGro M, Shikiar R, Revicki D . Defining and measuring quality of life in medicine. JAMA. 1998; 279(6):429-30; author reply 431. View

16.

Mols F, Aaronson N, Vingerhoets A, Coebergh J, Vreugdenhil G, Lybeert M . Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer. 2007; 109(8):1659-67. DOI: 10.1002/cncr.22581. View

17.

Oberg K, Astrup L, Eriksson B, Falkmer S, Falkmer U, Gustafsen J . Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol. 2004; 43(7):617-25. DOI: 10.1080/02841860410018575. View

18.

Loge J, Kaasa S . Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med. 1998; 26(4):250-8. View

19.

King M . The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 1996; 5(6):555-67. DOI: 10.1007/BF00439229. View

20.

Ware Jr J, Sherbourne C . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30(6):473-83. View